Kairos Pharma Income Statement (2024-2025) | KAPA

Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025
Revenue & cost
Revenue -0.02M-0.01M-0.54M100.00M
Operating items
Amortization - Intangibles 0.02M0.02M0.12M
Research & Development 0.17M0.06M0.01M0.17M0.49M0.50M
Selling, General & Administrative 0.12M0.16M0.37M1.27M0.77M0.96M
Operating Expenses 0.29M0.22M0.38M1.45M1.27M1.46M
Operating Income -0.29M-0.22M-0.38M-1.45M-1.27M-1.46M
EBIT -0.29M-0.22M-0.38M-1.45M-1.27M-1.46M
Non-operating items
Interest & Investment Income 0.00M0.03M
Non Operating Income -0.04M-0.03M-0.66M0.47M0.00M0.03M
Net income details
EBT -0.30M-0.23M-0.92M-1.58M-1.26M-1.42M
Profit After Tax -0.32M-0.25M-1.05M-0.98M-1.26M-1.42M
Income from Continuing Operations -0.30M-0.23M-0.92M-1.58M-1.26M-1.42M
Consolidated Net Income -0.30M-0.23M-0.92M-1.58M-1.26M-1.42M
Income towards Parent Company -0.30M-0.23M-0.92M-1.58M-1.26M-1.42M
Net Income towards Common Stockholders -0.30M-0.23M-0.92M-1.58M-1.26M-1.42M
Additional items
EPS (Basic) -0.03-0.02-0.08-0.14-0.08-0.08
EPS (Weighted Average and Diluted) -0.03-0.02-0.08-0.14-0.08-0.08
Shares Outstanding (Weighted Average) 10.56M10.56M10.91M11.36M15.88M17.21M
Shares Outstanding (Diluted Average) 10.56M10.56M10.91M11.36M15.88M17.21M
EBITDA -0.29M-0.22M-0.38M-1.45M-1.27M-1.46M
Interest Expenses 0.02M0.01M0.54M0.13M